Cationic macromolecules condense DNA into small nanoparticles and kind polyplex. The composition of the polyplex determines the endocytic course of, the intracellular routing and the destiny of the polyplex. Beforehand, oligochitosan-modified vectors with completely different protein moieties are used as gene supply vector and the varieties of protein moiety can affect the endosome escape capability and transfection effectivity. Among the many modified vectors, oligochitosan-modified bovine serum albumin (BSA) confirmed 90% transfection efficeincy in comparison with the modified zein and ovalbumin.
These knowledge inspired us to research the mechanism of internalization concerned within the superior transfection effectivity of modified BSA/ plasmid polyplex. The impact of particular endocytic inhibitors was studied in two adherent cell traces. The caveolae-mediated and lipid-mediated pathways play a big position within the polyplex internalization. Subsequent, a colocation of polyplex with lysosome was investigated within the presence of LysoTracker utilizing confocal microscopy.
As much as 70% of polyplex efficiently escaped the lysosome with out degradation. 4 non-adherent cell traces confirmed above than 60% transfection effectivity at an optimized vector/plasmid ratio. Furthermore, no important hemolytic impact was noticed as much as 500 μg/mL of cationic BSA, indicating no detectable cell membrane disruption. General, the hybrid biomacromolecule confirmed good intracellular supply and security in a mice mannequin.
Optimization of peptide-plasmid DNA vectors formulation for gene supply in most cancers remedy exploring design of experiments.
The sphere of gene remedy nonetheless attracts nice curiosity resulting from its potential therapeutic impact in the direction of probably the most lethal ailments, equivalent to most cancers. For most cancers gene remedy to be possible and viable in a scientific setting, the design and growth of an acceptable gene supply system is crucial. Peptide primarily based vectors, particularly, disclose to be promising for therapeutic gene launch. Following this, two completely different peptides, RALA and WRAP5, have been investigated primarily relating to their capability to kind complexes with a p53 encoding plasmid (pDNA) with appropriate properties for gene supply.
To deal with this problem, and after an preliminary screening research targeted on the dependence of pDNA complexation capability with the nitrogen to phosphate teams (N/P) ratio, a design of experiments (DoE) instrument has been employed. For every peptide/pDNA system, parameters equivalent to, the buffer pH and the N/P ratio have been thought of the DoE inputs and the vector dimension, zeta potential and pDNA complexation capability (CC) have been monitored as DoE outputs. The primary purpose was to search out the optimum experimental situations to attenuate particle sizes, in addition to, to maximise the optimistic floor fees of the formulated nanosystems and maximize the pDNA CC.
By means of the DoE methodology utilized, the optimum RALA/pDNA and WRAP5/pDNA formulations have been revealed and present attention-grabbing options associated to peptide construction and pDNA complexation capability. This work illustrates the nice utility of experimental design instruments in optimizing the formulation of peptide/pDNA vectors in a minimal variety of experiments offering related data for the event of extra appropriate and environment friendly gene supply methods. The brand new insights achieved on these carriers clearly instigate deeper analysis on gene remedy.
Novel Expression Vectors Based mostly on the pIGDM1 Plasmid.
Escherichia coli is likely one of the most generally used hosts for the manufacturing of heterologous proteins. Inside this host, the selection of cloning vector constitutes a key issue for a passable amplified expression of a goal gene. We aimed to develop novel, unpatented expression vectors that allow the steady upkeep and environment friendly overproduction of proteins in E. coli. A collection of expression vectors primarily based on the ColE1-like pIGDM1 plasmid have been constructed. The vectors named pIGDMCT7RS, pIGDM4RS and pIGDMKAN carry numerous antibiotic resistance genes: chloramphenicol, ampicillin or kanamycin, respectively. Two derivatives comprise the inducible T7 promoter whereas the third one bears the constitutive pms promoter from a scientific pressure of Klebsiella pneumoniae.
The pIGDM1-derivatives are appropriate with different ColE1-like plasmids generally utilized in molecular cloning. The pIGDMCT7RS and pIGDM4RS vectors comprise genes encoding AGA and AGG tRNAs, which complement the scarcity of those tRNAs, growing the effectivity of synthesis of heterologous proteins. In conclusion, pIGDMCT7RS, pIGDM4RS and pIGDMKAN vectors, with considerably improved options, together with compatibility with overwhelming majority of different plasmids, have been designed and constructed. They allow a high-level expression of a desired recombinant gene and due to this fact represent a possible, precious instrument for pharmaceutical corporations and analysis laboratories for their very own analysis or for the manufacturing of recombinant biopharmaceuticals.
Minimal plasmids play a necessary position in lots of intermediate steps in molecular biology. For instance, they can be utilized to assemble constructing blocks in artificial biology or be used as intermediate cloning plasmids that are perfect for PCR-based mutagenesis strategies. A small spine additionally opens up for added distinctive restriction enzyme cloning websites. Right here we describe the technology of pICOz, a 1185-bp absolutely useful high-copy cloning plasmid with an prolonged a number of cloning web site. We imagine that that is the smallest high-copy cloning vector ever described.
Single Plasmid-Based mostly, Upgradable, and Backward-Suitable Adenoviral Vector Programs.
Current adenoviral vector methods have two drawbacks. It’s labor-intensive and time-consuming to load a transgene in these methods, and transgene-harboring vectors are lifeless ends: they can’t be reused to assemble a vector carrying one other transgene or attaining new traits. To beat these shortcomings, single plasmid-based adenoviral vector methods have been constructed the place a singular PmeI web site was positioned on the place for insertion of the exogenous gene.
c-Myc(MYC275) Antibody |
|||
| BNC800275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF680 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC800275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF680 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC800699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF680 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC800699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF680 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC810275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF680R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC810275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF680R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC810699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF680R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC810699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF680R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC810909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF680R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC810909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF680R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC940275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF594 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC940275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF594 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC940699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF594 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC940699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF594 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC940909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF594 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC940909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF594 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC700275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF770 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC700275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF770 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC700699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF770 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC700699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF770 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC700909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF770 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC700909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF770 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC880699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF488A conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC880699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF488A conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC880909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF488A conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC880909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF488A conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC050699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF405M conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC050699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF405M conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC050909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF405M conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC050909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF405M conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC040699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF405S conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC040699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF405S conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC040909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF405S conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC040909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF405S conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC430275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF543 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC430275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF543 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC400275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF640R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC400275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF640R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC400699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF640R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC400699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF640R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC400909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF640R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC400909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF640R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC050275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF405M conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC050275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF405M conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCB0275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), Biotin conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCB0275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), Biotin conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCB0699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), Biotin conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCB0699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), Biotin conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCAP0909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCAP0909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCA0909-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against c-Myc(MYC909), APC conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCAP0275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCAP0275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCAP0699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCAP0699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCB0909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), Biotin conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCB0909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), Biotin conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC880275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF488A conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC880275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF488A conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCR0275-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against c-Myc(MYC275), RPE conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCR0699-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against c-Myc(MYC699), RPE conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCR0909-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against c-Myc(MYC909), RPE conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCP0275-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against c-Myc(MYC275), PerCP conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCP0699-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against c-Myc(MYC699), PerCP conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCP0909-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against c-Myc(MYC909), PerCP conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNUM0275-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against c-Myc(MYC275), 1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNUM0699-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against c-Myc(MYC699), 1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNUM0909-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against c-Myc(MYC909), 1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCH0909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCH0909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNUB0909-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against c-Myc(MYC909), Concentration: 0.2mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNUB0909-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against c-Myc(MYC909), Concentration: 0.2mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCH0275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCH0275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCH0699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCH0699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNUB0275-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against c-Myc(MYC275), Concentration: 0.2mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNUB0275-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against c-Myc(MYC275), Concentration: 0.2mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNUB0699-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against c-Myc(MYC699), Concentration: 0.2mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNUB0699-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against c-Myc(MYC699), Concentration: 0.2mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC040275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF405S conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC040275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF405S conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC550275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF555 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC550275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF555 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC550699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF555 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC550699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF555 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC610275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF660R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC610275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF660R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC610699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF660R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC610699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF660R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC610909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF660R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC610909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF660R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC680275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF568 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC680275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF568 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC470275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF647 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC470275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF647 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC470699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF647 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC470699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF647 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC550909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF555 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC550909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF555 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC430699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF543 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC430699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF543 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC430909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF543 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC430909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF543 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC680699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF568 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC680699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF568 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC680909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF568 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC680909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF568 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC470909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF647 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC470909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF647 conjugate, Concentration: 0.1mg/mL |
|||
anti- c-MYC antibody |
|||
| FNab01791 | FN Test | 100µg | EUR 702 |
|
Description: Antibody raised against c-MYC |
|||
Anti-c-Myc Antibody |
|||
| PB9092 | BosterBio | 100ug/vial | EUR 400.8 |
Anti-c-Myc Antibody |
|||
| PA1555 | BosterBio | 100ug/vial | EUR 352.8 |
Anti-c-MYC antibody |
|||
| PAab01791 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-C-myc Antibody |
|||
| 0912-2 | HUABIO | 100ul | EUR 189 |
|
Description: Myc is a family of regulator genes and proto-oncogenes that code for transcription factors. The Myc family consists of three related human genes: c-myc (MYC), l-myc (MYCL), and n-myc (MYCN). c-myc (also sometimes referred to as MYC) was the first gene to be discovered in this family, due to homology with the viral gene v-myc. In cancer, c-myc is often constitutively (persistently) expressed. This leads to the increased expression of many genes, some of which are involved in cell proliferation, contributing to the formation of cancer. A common human translocation involving c-myc is critical to the development of most cases of Burkitt lymphoma. Constitutive upregulation of Myc genes have also been observed in carcinoma of the cervix, colon, breast, lung and stomach. Myc is thus viewed as a promising target for anti-cancer drugs. Unfortunately, Myc possesses several features that render it undruggable such that any anti-cancer drugs for Myc dysregulation will require acting on the protein indirectly, i.e. targeting the mRNA for the protein rather than a small molecule that targets the protein itself. In the human genome, C-myc is located on chromosome 8 and is believed to regulate expression of 15% of all genes through binding on enhancer box sequences (E-boxes). In addition to its role as a classical transcription factor, N-myc may recruit histone acetyltransferases (HATs). This allows it to regulate global chromatin structure via histone acetylation. |
|||
Anti-c-myc antibody |
|||
| STJ180021 | St John's Laboratory | 0.1 ml | EUR 282 |
Anti-C-myc antibody |
|||
| STJ160092 | St John's Laboratory | 7 mL P | EUR 834 |
Anti-c-Myc antibody |
|||
| STJ119460 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene. |
|||
Anti-c-Myc antibody |
|||
| STJ97127 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to c-Myc. |
|||
Anti-c-Myc antibody |
|||
| STJ97962 | St John's Laboratory | 100 µl | EUR 280.8 |
|
Description: Mouse monoclonal to c-Myc. |
|||
Anti-c-Myc antibody |
|||
| STJ92355 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to c-Myc. |
|||
Anti-c-Myc antibody |
|||
| STJ92356 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: c-Myc is a protein encoded by the MYC gene which is approximately 48,8 kDa. c-Myc is localised to the nucleus. It is involved in signalling by NOTCH1, CDK-mediated phosphorylation and removal of Cdc6 and ERK signalling. It functions as a transcription factor that regulates transcription of specific target genes. It plays a role in cell cycle progression, apoptosis and cellular transformation. c-Myc is expressed in the nervous system, intestine, blood, liver and bone marrow. Mutations in the MYC gene may result in Burkitt lymphoma. STJ92356 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This polyclonal antibody detects endogenous levels of c-Myc protein. |
|||
Anti-c-Myc antibody |
|||
| STJ92357 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to c-Myc. |
|||
Anti-c-Myc antibody |
|||
| STJ92358 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to c-Myc. |
|||
Anti-c-Myc antibody |
|||
| STJ92359 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to c-Myc. |
|||
anti- MYC tag antibody |
|||
| FNab05456 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against MYC tag |
|||
anti- MYC-tag antibody |
|||
| FNab05462 | FN Test | 100µg | EUR 606.3 |
|
Description: Antibody raised against MYC-tag |
|||
Myc Antibody |
|||
| abx242911-100ul | Abbexa | 100 ul | EUR 477.6 |
Myc antibody |
|||
| 10R-10451 | Fitzgerald | 100 ug | EUR 522 |
|
Description: Mouse monoclonal Myc antibody |
|||
MYC antibody |
|||
| 10R-10606 | Fitzgerald | 100 ug | EUR 418.8 |
|
Description: Mouse monoclonal MYC antibody |
|||
MYC antibody |
|||
| 10R-1757 | Fitzgerald | 100 ug | EUR 614.4 |
|
Description: Mouse monoclonal MYC antibody |
|||
Myc antibody |
|||
| 10R-4914 | Fitzgerald | 100 ul | EUR 871.2 |
|
Description: Mouse monoclonal Myc antibody |
|||
Myc antibody |
|||
| 10R-4915 | Fitzgerald | 100 ul | EUR 829.2 |
|
Description: Mouse monoclonal Myc antibody |
|||
Myc antibody |
|||
| 10R-4916 | Fitzgerald | 100 ul | EUR 829.2 |
|
Description: Mouse monoclonal Myc antibody |
|||
Myc antibody |
|||
| 10R-7246 | Fitzgerald | 50 ug | EUR 337.2 |
|
Description: Mouse monoclonal Myc antibody |
|||
Myc antibody |
|||
| 20R-1901 | Fitzgerald | 50 ug | EUR 337.2 |
|
Description: Rabbit polyclonal Myc antibody |
|||
Myc antibody |
|||
| 20R-1902 | Fitzgerald | 50 ug | EUR 337.2 |
|
Description: Rabbit polyclonal Myc antibody |
|||
Myc antibody |
|||
| 20R-1903 | Fitzgerald | 50 ug | EUR 337.2 |
|
Description: Rabbit polyclonal Myc antibody |
|||
Myc antibody |
|||
| 20R-2131 | Fitzgerald | 50 ug | EUR 337.2 |
|
Description: Rabbit polyclonal Myc antibody |
|||
Myc antibody |
|||
| 20R-2218 | Fitzgerald | 50 ug | EUR 337.2 |
|
Description: Rabbit polyclonal Myc antibody |
|||
Myc antibody |
|||
| 20R-2219 | Fitzgerald | 50 ug | EUR 337.2 |
|
Description: Rabbit polyclonal Myc antibody |
|||
Myc antibody |
|||
| 20R-2220 | Fitzgerald | 50 ug | EUR 337.2 |
|
Description: Rabbit polyclonal Myc antibody |
|||
Myc antibody |
|||
| 70R-30593 | Fitzgerald | 100 ug | EUR 392.4 |
|
Description: Rabbit polyclonal Myc antibody |
|||
MYC Antibody |
|||
| BF0467 | Affbiotech | 200ul | EUR 540 |
The polymerase chain response (PCR) amplified transgene could possibly be cloned into PmeI-linearized beginning plasmids utilizing one step of Gibson meeting to generate goal adenoviral plasmids, which have been then prepared for virus rescue. This process was termed restriction meeting.